Tuesday, March 6, 2012

Pfizer Japan and Chugai receive positive Approval Recommendations for Xalkori and Pulmozyme respectively in Japan

Pfizer Japan and Chugai respectively received approval recommendations for Xalkori (ALK+ve NSCLC) and Pulmozyme (Cystic fibrosis). Both drugs have been designated orphan drug status. About 1,000-8,000 patients are diagnosed with ALK+ve NSCLCsuch disease annually in Japan. Xalkori is designated as an orphan drug.
About 10-15 patients are annually diagnosed with cystic fibrosis in Japan